Given the importance of anthracyclines in treating breast cancer, various strategies have been tried to prevent or ameliorate the cardiac toxicity associated with doxorubicin including the use of concurrent medications like angiotensin converting enzyme inhibitors (ACEI) (Cardinale et al. 2006; Bosch et al. 2013; Georgakopoulos et al. 2010), beta-blockers (Kalay et al. 2006), dexrazoxane (Swain et al. 1997), liposomal formulations of doxorubicin chemotherapy, or the alteration of doxorubicin infusion times (Blaes 2010). The gene discussed is ACE; the disease is breast cancer.